search
Back to results

Incorporating Nutrition, Vests, Education, and Strength Training in Bone Health (INVEST in Bone Health) (INVEST)

Primary Purpose

Weight Loss, Bone Health

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Vest
Resistance Exercise Training
weight loss program
Sponsored by
Wake Forest University Health Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Weight Loss focused on measuring nutrition, vest

Eligibility Criteria

60 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 60-85 years
  • BMI=30-40 kg/m^2 or BMI 27.0-<30.0 kg/m^2 plus one risk factor
  • Weight stability - no weight loss > 5% in past 6 months
  • No contraindications for safe and optimal participation in exercise training/vest use.
  • Approved for participation by Study Coordinator
  • Willing to provide informed consent; agree to all study procedures and assessments; Able to provide own transit to assessment/intervention visits
  • Willing to complete online/electronic study forms and participate in virtual group sessions, as needed.

Exclusion Criteria:

  • Weight greater than 450 lbs
  • Dependent on cane or walker: >2 falls (injurious on non-injurious) in past year
  • Any contraindications for participation in voluntary weight loss
  • Smoker (>1 cigarette/d or 4/wk within yr); Excessive alcohol use (>14 drinks/wk)
  • Participation in regular resistance training and/or high intensity/high impact aerobic exercise for >60 mins per day on > 5 days/week for the past 6 months
  • Evidence of cognitive impairment (MoCA<20)
  • Osteoporosis (self-report and on prescription medication, T-score < or = -2.5 on total hip, femoral neck, lumbar spine or distal radius scan at screening visit, or FRAX 10-year risk scores >3% for hip fracture or >20% for major osteoporotic fracture (TBS adjusted FRAX is preferable if available)
  • Self-reported prior spine, hip, wrist, or shoulder fracture after age 40 (except when caused by trauma or fall from height)
  • Chronic back/shoulder/knee pain with current or past (within 1 year) prescription medication use for at least 3 months
  • Severe, diagnosed arthritis (osteoarthritis, rheumatoid arthritis, or gout) with current or past (within 1 year) prescription medication use for at least 3 months
  • Past (ever) or planned (next 12 months) back surgery
  • Past (6 months prior) or planned (next 12 months) joint replacement surgery; or past (ever) unilateral or bilateral hip replacement surgery
  • Past (ever) metal device or fixation in the hip, pelvis, or femur
  • Uncontrolled hypertension (BP > 160/90 mmHg)
  • Current or recent past (within 1 year) severe symptomatic heart disease, uncontrolled angina, stroke, chronic respiratory disease requiring oxygen, neurological or hematological disease requiring treatment for at least 3 months in past year
  • Cancer requiring treatment in past year, except non-melanoma skin cancer
  • Low Vitamin D (<20 ng/mL)
  • Abnormal kidney or liver function (2x upper limits of normal)
  • eGFR<45 mL/min/1.73m2,
  • Anemia (Hb <13 g/dL in men/<12 g/dL in women)
  • Uncontrolled diabetes (fasting glucose > 140 mg/dL)
  • Regular use of: growth hormones, weight loss medications, oral steroids, insulin, or prescription osteoporosis medications in the past year
  • No home computer, laptop or tablet with reliable home internet OR no smartphone (touch-screen enabled phone) with reliable unlimited mobile internet
  • Involved in another behavioral/interventional research study, weight loss program, or undergoing physical therapy.
  • Unable to tolerate diet, vest, or CT scan (claustrophobia)
  • Judged unsuitable for the trial for any reason by clinic staff

Sites / Locations

  • Wake Forest University School of Medicine

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Active Comparator

Arm Label

Weight Loss plus Vest

Weight Loss Plus Resistance Exercise Training

Weight Loss

Arm Description

Outcomes

Primary Outcome Measures

Change in total hip trabecular volumetric bone mineral density (vBMD)
measured in mg/cm3 during computed tomography (CT) scan

Secondary Outcome Measures

Change in total hip trabecular volumetric bone mineral density (vBMD)
measured in mg/cm3 during computed tomography (CT) scan
Change in femoral neck volumetric bone mineral density (vBMD)
measured in mg/cm3 during computed tomography (CT) scan
Change in lumbar spine volumetric bone mineral density (vBMD)
measured in mg/cm3 during computed tomography (CT) scan
Trabecular bone score (TBS)
measurement taken during dual energy x-ray absorptiometry (DXA) scan; Trabecular Bone Score is a measure of bone architecture that has been shown to be an independent risk factor for fracture. The measure is unitless, and ranges from 1.0-1.6, where an elevated TBS greater than or equal to 1.3 appears to represent strong, fracture-resistant bone architecture, while a low TBS less than or equal to 1.2 reflects weak, fracture-prone bone architecture.
Change in total hip areal bone mineral density (aBMD)
measured in g/cm2 during dual energy x-ray absorptiometry (DXA) scan
Change in femoral neck areal bone mineral density (aBMD)
measured in g/cm2 during dual energy x-ray absorptiometry (DXA) scan
Change in distal radius areal bone mineral density (aBMD)
measured in g/cm2 during dual energy x-ray absorptiometry (DXA) scan
Change in lumbar spine areal bone mineral density (aBMD)
measured in g/cm2 during dual energy x-ray absorptiometry (DXA) scan
Change in total body fat mass (kg)
measurement taken during dual energy x-ray absorptiometry (DXA) scan
Change in total body lean mass (kg)
measurement taken during dual energy x-ray absorptiometry (DXA)

Full Information

First Posted
August 29, 2019
Last Updated
June 27, 2023
Sponsor
Wake Forest University Health Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT04076618
Brief Title
Incorporating Nutrition, Vests, Education, and Strength Training in Bone Health (INVEST in Bone Health)
Acronym
INVEST
Official Title
Incorporating Nutrition, Vests, Education, and Strength Training in Bone Health (INVEST in Bone Health)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
August 12, 2020 (Actual)
Primary Completion Date
March 31, 2024 (Anticipated)
Study Completion Date
March 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Wake Forest University Health Sciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The main goal of the proposed study is to compare the effects of weight loss (WL) alone with WL plus weighted vest use or WL plus resistance exercise training (RT) on indicators of bone health and subsequent fracture risk.
Detailed Description
The study team proposes that a 12 month trial in 150 older (60-85 years) adults with obesity (Body mass index or BMI=30-40 kg/m2 OR 27.0-<30 kg/m² and one obesity-related risk factor) randomized to one of three interventions (n=50/group): WL alone (WL; caloric restriction targeting 10% WL); WL plus weighted vest use (WL+Vest); targeting ≥8 hours/day, weight replacement titrated up to 10% WL); or, WL plus structured RT (WL+RT; 3 days/week). Total hip trabecular volumetric bone mineral density (vBMD) is the primary outcome. This outcome will be complemented by exploratory assessment of several fracture-related risk factors, including: (1) femoral neck and lumbar spine vBMD, cortical thickness, finite element modeling of bone strength, and regional fat and muscle volumes, measured by CT; (2) areal bone mineral density (aBMD) at the total hip, femoral neck, lumbar spine, and distal radius; trabecular bone score; and total body fat/lean masses, measured by dual energy x-ray absorptiometry (DXA); (3) muscle function and strength; (4) biomarkers of bone turnover; and (5) bone-regulating hormones/cytokines known to influence bone metabolism during WL. Therefore, the investigators Specific Aims are to: Aim 1: Determine the effects of WL+Vest compared to WL and WL+RT on 12 month change in total hip trabecular vBMD. Despite similar reductions in total body weight, Hypothesis 1: Participants in the WL+Vest group will show attenuated losses of total hip trabecular vBMD versus WL; and Hypothesis 2: Loss in total hip trabecular vBMD will be no greater in WL+Vest compared to WL+RT. Aim 2: Explore the effects of WL+Vest compared to WL and WL+RT on the 12 month change in fracture-related risk factors. Despite similar reductions in total body weight, we hypothesize that WL+Vest and WL+RT will demonstrate improvements in fracture-related risk factors compared to WL.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Weight Loss, Bone Health
Keywords
nutrition, vest

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
150 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Weight Loss plus Vest
Arm Type
Experimental
Arm Title
Weight Loss Plus Resistance Exercise Training
Arm Type
Active Comparator
Arm Title
Weight Loss
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Vest
Intervention Description
Weighted Vest worn > or = 8 hours per day
Intervention Type
Behavioral
Intervention Name(s)
Resistance Exercise Training
Intervention Description
Structured exercise training 3 days a week
Intervention Type
Behavioral
Intervention Name(s)
weight loss program
Intervention Description
a 24-week intensive phase (with weekly dietary classes) followed by a 27-week transition phase (with biweekly dietary classes)
Primary Outcome Measure Information:
Title
Change in total hip trabecular volumetric bone mineral density (vBMD)
Description
measured in mg/cm3 during computed tomography (CT) scan
Time Frame
12 months from baseline
Secondary Outcome Measure Information:
Title
Change in total hip trabecular volumetric bone mineral density (vBMD)
Description
measured in mg/cm3 during computed tomography (CT) scan
Time Frame
6 months from baseline
Title
Change in femoral neck volumetric bone mineral density (vBMD)
Description
measured in mg/cm3 during computed tomography (CT) scan
Time Frame
12 months from baseline
Title
Change in lumbar spine volumetric bone mineral density (vBMD)
Description
measured in mg/cm3 during computed tomography (CT) scan
Time Frame
12 months from baseline
Title
Trabecular bone score (TBS)
Description
measurement taken during dual energy x-ray absorptiometry (DXA) scan; Trabecular Bone Score is a measure of bone architecture that has been shown to be an independent risk factor for fracture. The measure is unitless, and ranges from 1.0-1.6, where an elevated TBS greater than or equal to 1.3 appears to represent strong, fracture-resistant bone architecture, while a low TBS less than or equal to 1.2 reflects weak, fracture-prone bone architecture.
Time Frame
12 months from baseline
Title
Change in total hip areal bone mineral density (aBMD)
Description
measured in g/cm2 during dual energy x-ray absorptiometry (DXA) scan
Time Frame
12 months from baseline
Title
Change in femoral neck areal bone mineral density (aBMD)
Description
measured in g/cm2 during dual energy x-ray absorptiometry (DXA) scan
Time Frame
12 months from baseline
Title
Change in distal radius areal bone mineral density (aBMD)
Description
measured in g/cm2 during dual energy x-ray absorptiometry (DXA) scan
Time Frame
12 months from baseline
Title
Change in lumbar spine areal bone mineral density (aBMD)
Description
measured in g/cm2 during dual energy x-ray absorptiometry (DXA) scan
Time Frame
12 months from baseline
Title
Change in total body fat mass (kg)
Description
measurement taken during dual energy x-ray absorptiometry (DXA) scan
Time Frame
12 months from baseline
Title
Change in total body lean mass (kg)
Description
measurement taken during dual energy x-ray absorptiometry (DXA)
Time Frame
12 months from baseline
Other Pre-specified Outcome Measures:
Title
Mid-thigh muscle density measured in Hounsfield units (HU)
Description
measurement taken during computed tomography (CT) scan
Time Frame
12 months from baseline
Title
Mid- thigh intermuscular fat cross sectional area (CSA) (cm2)
Description
measurement taken during computed tomography (CT) scan
Time Frame
12 months from baseline
Title
Cortical thickness (mm)
Description
measurement taken during computed tomography (CT) scan
Time Frame
12 months from baseline
Title
Finite element (FE) modeling of bone strength measured in Kilonewton (kN)
Description
measurement taken during computed tomography (CT) scan
Time Frame
12 months from baseline
Title
Mid-thigh muscle CSA (cm2)
Description
measurement taken during computed tomography (CT) scan
Time Frame
12 months from baseline
Title
L3 muscle density measured in HU
Description
measurement taken during computed tomography (CT) scan
Time Frame
12 months from baseline
Title
L3 intermuscular fat CSA (cm2)
Description
measurement taken during computed tomography (CT) scan
Time Frame
12 months from baseline
Title
L3 muscle CSA (cm2)
Description
measurement taken during computed tomography (CT) scan
Time Frame
12 months from baseline
Title
Procollagen 1 Intact N-Terminal Propeptide (P1NP) (ug/L)
Description
Biomarkers of bone turnover measured via blood specimen
Time Frame
12 months from baseline
Title
C-terminal telopeptide (CTX) (pg/mL)
Description
Biomarkers of bone turnover measured via blood specimen
Time Frame
12 months from baseline
Title
D3-Creatine derived muscle mass measured in kg
Description
measurement taken via urine sample
Time Frame
12 months from baseline
Title
Gait speed
Description
measured in m/s during the 400 meter walk test
Time Frame
12 months from baseline
Title
expanded Short Physical Performance Battery (eSPPB)
Description
The SPPB is a measure of balance, walking speed, and ability to stand from a chair. It provides a global measure of overall physical function and is a good predictor of future disability, institutionalization, and mortality in older persons. The SPPB score is calculated by assigning each of the test measures (balance, walking speed, and chair stands) a score from 0 (unable to do) to 4 (best) and then adding these scores together for a total score ranging from 0 to 12. An SPPB score less than 10 identifies persons at higher risk for mobility disability.
Time Frame
12 months from baseline
Title
Timed-Up-and-Go (TUG)
Description
measured in seconds to assess physical performance; measures the time the participant takes to stand up from a standard chair, walk 3 meters, turn, walk back to the chair, and sit down again.
Time Frame
12 months from baseline
Title
Stair climbing time
Description
measured in seconds using the participant's fastest time achieved to climb a 12 step staircase in two trials.
Time Frame
12 months from baseline
Title
Lower extremity muscle strength
Description
measured using an isokinetic dynamometer with the participant sitting and the hips and knee flexed at 90°. Participants will be asked to extend the knee and push as hard as possible against the resistance pad. Strength is expressed as peak torque (Nm)
Time Frame
12 months from baseline
Title
Grip strength
Description
measured twice in each hand to the nearest two kg using an isometric Jamar Hydraulic Hand Dynamometer with the mean value from the stronger hand used
Time Frame
12 months from baseline
Title
Cognitive Assessment
Description
measured using the Montreal Cognitive Assessment (MOCA) with scores ranging from 0-30, with a score of 26 and higher generally considered normal.
Time Frame
12 months from baseline
Title
Fatigability
Description
measured using the Pittsburgh Fatigability scale, which is a 10-item questionnaire that assesses fatigability, or the rate at which a person experiences mental or physical fatigue in the context of a standardized task. The scale ranges from 0-5, where those who exhibit more fatigability, score of 5, are more likely to limit activities of daily living and to reduce exertion during physical activities.
Time Frame
12 months from baseline
Title
Pain and Fatigue
Description
measured using The Patient-Reported Outcomes Measurement Information System (PROMIS) instrument is an 8-item short-form that assesses pain and fatigue over the past 7 days. The scale ranges from 1-5, with higher scores indicated the presence of pain and fatigue.
Time Frame
12 months from baseline
Title
Physical activity among older adults
Description
The CHAMPS questionnaire is a 40-43-item tool that assesses weekly frequency and duration of a variety of lifestyle physical activities that are appropriate for older adults. The purpose of this questionnaire is to evaluate the effectiveness of interventions to increase lifestyle physical activity among older adults. Physical activities are given a METS score, ranging from 2.0-7.0, where activities with an activities of moderate intensity (METS) score of 3.0 or higher, are considered moderate intensity.
Time Frame
12 months from baseline
Title
Overall limb loading
Description
measured in Newtons via force-sensing insoles to assess overall limb loading and to determine if participants receive enough loading to prevent bone loss from resistance training and weighted vest use when compared to weight loss alone.
Time Frame
6 months from baseline
Title
Overall satisfaction participating in the optional insole visits
Description
overall satisfaction measured by a scale from 1-5 with a higher score indicating greater satisfaction
Time Frame
6 months from baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 60-85 years BMI=30-40 kg/m^2 or BMI 27.0-<30.0 kg/m^2 plus one risk factor Weight stability - no weight loss > 5% in past 6 months No contraindications for safe and optimal participation in exercise training/vest use. Approved for participation by Study Coordinator Willing to provide informed consent; agree to all study procedures and assessments; Able to provide own transit to assessment/intervention visits Willing to complete online/electronic study forms and participate in virtual group sessions, as needed. Exclusion Criteria: Weight greater than 450 lbs Dependent on cane or walker: >2 falls (injurious on non-injurious) in past year Any contraindications for participation in voluntary weight loss Smoker (>1 cigarette/d or 4/wk within yr); Excessive alcohol use (>14 drinks/wk) Participation in regular resistance training and/or high intensity/high impact aerobic exercise for >60 mins per day on > 5 days/week for the past 6 months Evidence of cognitive impairment (MoCA<20) Osteoporosis (self-report and on prescription medication, T-score < or = -2.5 on total hip, femoral neck, lumbar spine or distal radius scan at screening visit, or fracture risk assessment tool (FRAX) 10-year risk scores >3% for hip fracture or >20% for major osteoporotic fracture (TBS adjusted FRAX is preferable if available) Self-reported prior spine, hip, wrist, or shoulder fracture after age 40 (except when caused by trauma or fall from height) Chronic back/shoulder/knee pain with current or past (within 1 year) prescription medication use for at least 3 months Severe, diagnosed arthritis (osteoarthritis, rheumatoid arthritis, or gout) with current or past (within 1 year) prescription medication use for at least 3 months Past (ever) or planned (next 12 months) back surgery Past (6 months prior) or planned (next 12 months) joint replacement surgery; or past (ever) unilateral or bilateral hip replacement surgery Past (ever) metal device or fixation in the hip, pelvis, or femur Uncontrolled hypertension (BP > 160/90 mmHg) Current or recent past (within 1 year) severe symptomatic heart disease, uncontrolled angina, stroke, chronic respiratory disease requiring oxygen, neurological or hematological disease requiring treatment for at least 3 months in past year Cancer requiring treatment in past year, except non-melanoma skin cancer Low Vitamin D (<20 ng/mL) Abnormal kidney or liver function (2x upper limits of normal) estimated glomerular filtration rate (eGFR)<45 mL/min/1.73m2, Anemia (Hb <13 g/dL in men/<12 g/dL in women) Uncontrolled diabetes (fasting glucose > 140 mg/dL) Regular use of: growth hormones, weight loss medications, oral steroids, insulin, or prescription osteoporosis medications in the past year No home computer, laptop or tablet with reliable home internet OR no smartphone (touch-screen enabled phone) with reliable unlimited mobile internet Involved in another behavioral/interventional research study, weight loss program, or undergoing physical therapy. Unable to tolerate diet, vest, or CT scan (claustrophobia) Judged unsuitable for the trial for any reason by clinic staff
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kristen Beavers, PhD, MPH, RD
Organizational Affiliation
Wake Forest University Health Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Wake Forest University School of Medicine
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33631359
Citation
Miller RM, Beavers DP, Cawthon PM, Crotts C, Fanning J, Gerosa J, Greene KA, Hsieh KL, Kiel J, Lawrence E, Lenchik L, Lynch SD, Nesbit BA, Nicklas BJ, Weaver AA, Beavers KM. Incorporating Nutrition, Vests, Education, and Strength Training (INVEST) in Bone Health: Trial Design and Methods. Contemp Clin Trials. 2021 May;104:106326. doi: 10.1016/j.cct.2021.106326. Epub 2021 Feb 22.
Results Reference
derived

Learn more about this trial

Incorporating Nutrition, Vests, Education, and Strength Training in Bone Health (INVEST in Bone Health)

We'll reach out to this number within 24 hrs